Rosiglitazone enhances fluorouracil-induced apoptosis of HT-29 cells by activating peroxisome proliferator-activated receptor γ

World Journal of Gastroenterology

Volumn 13, Issue 10, 2007, Pages 1534-1540

  Zhang, Yan Qin ^a   Tang, Xiao Qing ^b   Sun, Li ^a   Dong, Lin ^a   Qin, Yong ^a   Liu, Hua Qing ^a   Xia, Hong ^a   Cao, Jian Guo ^a  

^a UNIVERSITY OF SOUTH CHINA   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Apoptosis; Colon cancer; Fluorouracil; Rosiglitazone

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ACRIDINE ORANGE; ETHIDIUM BROMIDE; FLUOROURACIL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PROTEIN BAX; PROTEIN BCL 2; ROSIGLITAZONE; TRYPAN BLUE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN HT29; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN EXPRESSION; STAINING; UPREGULATION; WESTERN BLOTTING;

EID: 34247626779     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v13.i10.1534     Document Type: Article

References (32)

1. Austin RP, Barton P, Cockroft SL, Wenlock MC, Riley RJ. The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab Dispos 2002; 30: 1497-1503
2. Shin YK, Yoo BC, Chang HJ, Jeon E, Hong SH, Jung MS, Lim SJ, Park JG. Down-regulation of mitochondrial F1F0-ATP synthase in human colon cancer cells with induced 5-fluorouracil resistance. Cancer Res 2005; 65: 3162-3170
3. Akbulut H, Tang Y, Maynard J, Zhang L, Pizzorno G, Deisseroth A. Vector targeting makes 5-fluorouracil chemotherapy less toxic and more effective in animal models of epithelial neoplasms. Clin Cancer Res 2004; 10: 7738-7746
4. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 1994; 12: 960-969
5. Thirion P, Michiels S, Pignon JP, Buyse M, Braud AC, Carlson RW, O'Connell M, Sargent P, Piedbois P. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004; 22: 3766-3775
6. Mikhail NE, Cope D. Initiation of insulin in patients with type 2 diabetes failing oral therapy: response to Raskin and Janka. Diabetes Care 2005; 28: 1537-8; author reply 1538
7. Lee S, Kim W, Moon SO, Sung MJ, Kim DH, Kang KP, Jang YB, Lee JE, Jang KY, Park SK. Rosiglitazone ameliorates cisplatin-induced renal injury in mice. Nephrol Dial Transplant 2006; 21: 2096-2105
8. Strowig SM, Raskin P. The effect of rosiglitazone on overweight subjects with type 1 diabetes. Diabetes Care 2005; 28: 1562-1567
9. Koeffler HP. Peroxisome proliferator-activated receptor ganuna and cancers. Clin Cancer Res 2003; 9: 1-9
10. Cox PJ, Ryan DA, Hollis FJ, Harris AM, Miller AK, Vousden M, Cowley H. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab Dispos 2000; 28: 772-780
11. Tugwood JD, Issemann I, Anderson RG, Bundell KR, McPheat WL, Green S. The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. EMBO J 1992; 11: 433-439
12. Fruchart JC, Duriez P, Staels B. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol 1999; 10: 245-257
13. Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd Z, Fruchart JC, Chapman.J, Najib J, Staels B. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem 1998; 273: 25573-25580
14. Chen GG, Lee JF, Wang SH, Chan UP, Ip PC, Lau WY. Apoptosis induced by activation of peroxisome-proliferator activated receptor-gamma is associated with Bcl-2 and NF-kappaB in human colon cancer. Life Sci 2002; 70: 2631-2646
15. Cao JG, Tang XQ, Shi SH. Multidrug resistance reversal in human gastric carcinoma cells by neferine. World J Gastroenterol 2004; 10: 3062-3064
16. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55
17. Hashimoto Y, Shimada Y, Itami A, Ito T, Kawamura J, Kawabe A, Kaganoi J, Maeda M, Watanabe G, Imamura M. Growth inhibition through activation of peroxisome proliferator-activated receptor gamma in human oesophageal squamous cell carcinoma. Eur J Cancer 2003; 39: 2239-2246
18. Tang XQ, Bi H, Feng JQ, Cao JG. Effect of curcumin on multidrug resistance in resistant human gastric carcinoma cell line SGC7901/VCR. Acta Pharmacol Sin 2005; 26: 1009-1016
19. Hashimoto Y, Shimada Y, Itami A, Ito T, Kawamura J, Kawabe A, Kaganoi J, Maeda M, Watanabe G, Imamura M. Growth inhibition through activation of peroxisome proliferator-activated receptor gamma in human oesophageal squamous cell carcinoma. Eur J Cancer 2003; 39: 2239-2246
20. Li MY, Deng H, Zhao JM, Dai D, Tan XY, PPARgamma pathway activation results in apoptosis and COX-2 inhibition in HepG2 cells. World J Gastroenterol 2003; 9: 1220-1226
21. Ferruzzi P, Ceni E, Tarocchi M, Grappone C, Milani S, Galli A, Fiorelli G, Serio M, Mannelli M. Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R. J Clin Endocrinol Metab 2005; 90: 1332-1339
22. Valentiner U, Carlsson M, Erttmann R, Hildebrandt H, Schumacher U. Ligands for the peroxisome proliferator-activated receptor-gamma have inhibitory effects on growth of human neuroblastoma cells in vitro. Toxicology 2005; 213: 157-168
23. Shiau CW, Yang CC, Kulp SK, Chen KF, Chen CS, Huang JW, Chen CS. Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma. Cancer Res 2005; 65: 1561-1569
24. Okabe H, Tsujimoto H, Fukushima M. The correlation between thymidylate synthase expression and cytotoxicity of 5-fluorouracil in human cancer cell lines: study using polyclonal antibody against recombinant human thymidylate synthase. Gan To Kagaku Ryoho 1997; 24: 705-712
25. Violette S, Poulain L, Dussaulx E, Pepin D, Faussat AM, Chambaz J, Lacorte JM, Staedel C, Lesuffleur T. Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and BcI-X(L) in addition to Bax and p53 status. Int J Cancer 2002; 98: 498-504
26. Liu R, Page C, Beidler DR, Wicha MS, Nunez G. Overexpression of Bcl-x(L) promotes chemotherapy resistance of mammary tumors in a syngeneic mouse model. Am J Pathol 1999; 155: 1861-1867
27. Shi X, Liu S, Kleeff J, Friess H, Buchler MW. Acquired resistance of pancreatic cancer cells towards 5-Fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology 2002, 62: 354-362
28. Bartholomeusz C, Itamochi H, Yuan LX, Esteva FJ, Wood CG, Terakawa N, Hung MC, Ueno NT. Bcl-2 antisense oligonucleotide overcomes resistance to E1A gene therapy in a low HER2-expressing ovarian cancer xenograft model. Cancer Res 2005; 65: 8406-8413
29. Zhu H, Zhang L, Huang X, Davis JJ, Jacob DA, Teraishi F, Chiao P, Fang B. Overcorming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms. Mol Ther 2004; 9: 666-673
30. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998; 281: 1322-1326
31. Kirkin V, Joos S, Zornig M. The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta 2004; 1644: 229-249
32. Sultana H, Kigawa J, Kanamori Y, Itamochi H, Oishi T, Sato S, Kamazawa S, Ohwada M, Suzuki M, Terakawa N. Chemosensitivity and p53-Bax pathway-mediated apoptosis in patients with uterine cervical cancer. Ann Oncol 2003; 14: 214-219